Literature DB >> 28458253

Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Mahasweta Gooptu1, John Koreth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28458253      PMCID： PMC5477598          DOI： 10.3324/haematol.2017.165266

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Authors:  R A Nash; J H Antin; C Karanes; J W Fay; B R Avalos; A M Yeager; D Przepiorka; S Davies; F B Petersen; P Bartels; D Buell; W Fitzsimmons; C Anasetti; R Storb; V Ratanatharathorn
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

3.  Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.

Authors:  Per Ljungman; Rafael de La Camara; Noel Milpied; Liisa Volin; Charlotte A Russell; Adam Crisp; Alison Webster
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

4.  A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Authors:  Johan Törlén; Olle Ringdén; Karin Garming-Legert; Per Ljungman; Jacek Winiarski; Kari Remes; Maija Itälä-Remes; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

5.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

6.  Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

Authors:  Areej El-Jawahri; Shuli Li; Joseph H Antin; Thomas R Spitzer; Philippe A Armand; John Koreth; Sarah Nikiforow; Karen K Ballen; Vincent T Ho; Edwin P Alyea; Bimalangshu R Dey; Steven L McAfee; Brett E Glotzbecker; Robert J Soiffer; Corey S Cutler; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-31       Impact factor: 5.742

7.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

Authors:  Javier Bolaños-Meade; Brent R Logan; Amin M Alousi; Joseph H Antin; Kate Barowski; Shelly L Carter; Steven C Goldstein; Elizabeth O Hexner; Mary M Horowitz; Stephanie J Lee; John E Levine; Margaret L MacMillan; Paul J Martin; Adam M Mendizabal; Ryotaro Nakamura; Marcelo C Pasquini; Daniel J Weisdorf; Peter Westervelt; Vincent T Ho
Journal:  Blood       Date:  2014-08-28       Impact factor: 22.113

8.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

Authors:  M A Slavin; B Osborne; R Adams; M J Levenstein; H G Schoch; A R Feldman; J D Meyers; R A Bowden
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Authors:  Waleed Sabry; Richard Le Blanc; Annie-Claude Labbé; Guy Sauvageau; Stephen Couban; Thomas Kiss; Lambert Busque; Sandra Cohen; Silvy Lachance; Denis-Claude Roy; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2009-06-10       Impact factor: 5.742

10.  Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.

Authors:  Panayiotis D Ziakas; Fainareti N Zervou; Ioannis M Zacharioudakis; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240
View more
  1 in total

1.  Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation.

Authors:  Kota Yoshifuji; Kyoko Inamoto; Yuko Kiridoshi; Kozue Takeshita; Satoshi Sasajima; Yukiko Shiraishi; Yuko Yamashita; Yuko Nisaka; Yukari Ogura; Rie Takeuchi; Takashi Toya; Aiko Igarashi; Yuho Najima; Noriko Doki; Takeshi Kobayashi; Kazuteru Ohashi; Wataru Suda; Koji Atarashi; Atsushi Shiota; Masahira Hattori; Kenya Honda; Kazuhiko Kakihana
Journal:  Blood Adv       Date:  2020-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.